Company Focus
IQVIA INC.
Latest IQVIA INC. News
Pharmaceutical
Digital health stakeholders - including developers, policymakers, payers, and providers - are actively shaping and accelerating the adoption of digital health solutions, according to a new report from IQVIA. 12 December 2025
Related News
Insights
Company Spotlight
A U.S.-based clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company conducts its research and development activities primarily in the United States, with clinical programs run through international trial networks as appropriate.
Latest News & Features of interest to IQVIA INC.
Biotechnology
Janux Therapeutics’ shares closed up 14% at $15.14, after it announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. 23 January 2026
Biotechnology
UK pharma major GSK’s Nucala (mepolizumab) has recently received approval in China as add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD), expanding the shift in treatment access by allowing use at a lower blood eosinophil threshold. 22 January 2026
Biotechnology
US clinical-stage biotech Corxel Pharmaceuticals, dedicated to developing innovative therapies for patients with cardiometabolic conditions around the world, today announced the successful completion of its Series D1 financing, raising up to $287 million in capital. 22 January 2026
Biotechnology
San Francisco-based Mendra, a biopharma aiming to advance promising therapies for rare disease medicines, has announced its launch in conjunction with the closing of an $82 million oversubscribed Series A financing. 22 January 2026
Pharmaceutical
Texas, USA-based IntraBio revealed that the European Commission granted marketing authorization to Aqneursa (levacetylleucine) for the treatment of neurological manifestations of Niemann-Pick Type C (NPC) disease, following a positive opinion from the European Medicines Agency (EMA) human medicines committee, CHMP. 22 January 2026
Pharmaceutical
The Gates Foundation, Novo Nordisk Foundation, and Wellcome have said they will award $60 million in new grant funding over the next three years to support early-stage research aimed at speeding antibiotic discovery, as antimicrobial resistance keeps eroding the usefulness of existing drugs. 22 January 2026
Pharmaceutical
DelveInsight says the cystinosis treatment market across the USA, EU4, UK and Japan totaled about $250 million in 2024, with the USA accounting for roughly 84% of sales. The research group also estimates 1,540 diagnosed prevalent cases across those markets in 2024, underscoring how concentrated care remains in specialist metabolic and nephrology centers. 22 January 2026
Pharmaceutical
Menkes disease is a rare, X-linked genetic disorder caused by mutations in the ATP7A gene, which impair copper transport within the body. If left untreated, this defect leads to critically low copper levels in multiple tissues, resulting in severe neurodevelopmental impairment, connective tissue abnormalities, seizures, and typically early childhood mortality. 22 January 2026
Pharmaceutical
South Korean vaccine maker SK bioscience has announced that it is advancing the development of a Zaire ebolavirus vaccine under a new collaboration supported by the Coalition for Epidemic Preparedness Innovations (CEPI). 22 January 2026
Biosimilars
India’s Zydus Lifesciences, an innovation-led life-sciences company with an international presence, has launched the world’s first biosimilar of nivolumab in India under the brand name Tishtha, reinforcing the company’s growing capability in advanced biologics and immuno-oncology. 22 January 2026
Latest In Brief for IQVIA INC.
Biosimilars
India’s Sun Pharma has addressed speculation regarding a potential $10 billion acquisition of US firm Organon. 20 January 2026
Latest Relevant Ones To Watch News
The 11.7% economic interest in specialist HIV company ViiV Healthcare that is currently held by US pharma giant Pfizer is to be replaced with an investment by Japanese drugmaker Shionogi, it has been announced. 20 January 2026
20 January 2026
16 January 2026
15 January 2026
13 January 2026
8 January 2026
Relevant Ones to Watch Companies
Refine search
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze